Welcome to our dedicated page for Impact Biomedical SEC filings (Ticker: IBO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Impact BioMedical Inc. (IBO), a Nevada-incorporated biotechnology company listed on the NYSE American. These regulatory documents offer detailed insight into the company’s governance, capital structure, and strategic transactions, and are a key resource for investors analyzing IBO.
Impact BioMedical’s annual and quarterly reports, such as its Form 10-K referenced in proxy materials, describe the company’s business model of discovering, confirming, and patenting technologies for biopharmaceutical and consumer healthcare and wellness applications. These filings typically discuss the company’s technology platforms, risk factors, and financial condition in more depth than press releases.
The company’s definitive proxy statements (DEF 14A) provide information on corporate governance, director and executive officer roles, board committees, executive compensation, and stockholder voting procedures. For example, the 2025 proxy statement outlines the agenda for the annual meeting, including director elections, ratification of the independent registered public accounting firm, and an advisory vote on executive compensation, as well as details about majority ownership by DSS BioHealth Securities, Inc.
Current reports on Form 8-K are especially important for tracking material events at Impact BioMedical. Recent 8-K filings describe the entry into a Merger and Share Exchange Agreement with Dr Ashleys entities and a newly formed PubCo, including the planned structure under which Impact BioMedical and Dr Ashleys would become wholly owned subsidiaries of PubCo. Other 8-Ks report on matters such as the conversion of Series A Convertible Preferred Stock into common stock and the results of the 2025 annual meeting of stockholders.
Through this filings page, users can also review information relevant to capital structure and ownership, including voting arrangements, preferred stock designations, and support agreements related to the planned merger. Insider ownership and changes in control are discussed in proxy statements and referenced SEC reports.
Stock Titan’s platform surfaces these filings as they are posted to EDGAR and can pair them with AI-powered summaries to help explain complex sections, such as merger terms, voting requirements, or compensation disclosures. Investors interested in Impact BioMedical’s strategic merger, governance practices, or equity structure can use this page to locate the underlying documents, including 10-Ks, 10-Qs, 8-Ks, and DEF 14A filings, and rely on AI-generated highlights to quickly understand the key points.
Impact BioMedical, Inc. (IBO) filed a DEF 14C Definitive Information Statement that notifies shareholders of certain corporate actions and discloses ownership and director/officer compensation. The filing states the corporate action(s) will become effective no sooner than 20 days after mailing the Definitive Information Statement as required under Nevada law. Significant disclosed ownership includes DSS, Inc. holding 545,024 shares (4.5%) and the group of all officers and directors holding 95,779 shares (<1%). Reported compensation items include Mark Suseck $158,689 (2024), Todd D. Macko $555 (2024), and multiple directors each receiving $2,175 for the period shown. The document is signed by CEO Frank D. Heuszel in Houston on September 8, 2025. The filing appears focused on notice, ownership, and compensation disclosures rather than earnings or transactions.
Impact BioMedical filed a Preliminary Information Statement regarding corporate actions that will become effective no sooner than 20 days after mailing a Definitive Information Statement to stockholders. The filing discloses beneficial ownership snapshots showing DSS, Inc. holds 545,024 shares (4.5%) and that most named insiders and directors hold less than 1% individually. Director fees are listed at $1,250 cash plus $925 in other compensation for several directors, totaling $2,175 each. Executive pay detail shows Mark Suseck with total 2024 compensation of $158,689 and Todd D. Macko with $555 in 2024. The document includes signatures and appears to be a standard preliminary disclosure under the Exchange Act and Nevada Revised Statutes.
Impact BioMedical, Inc. reported a six-month net loss of $15,631,000 for the period ended June 30, 2025, versus a loss of $1,880,000 a year earlier, driven primarily by a $12,942,000 fair-value adjustment on a related-party note payable. Operating loss for the six months was $2,165,000 while total revenue was nominal at $7,000, reflecting limited commercial sales activity.
At June 30, 2025, total assets were $19.06 million (including $17.565 million of net intangible assets for developed technologies), cash was $624,000, and the related-party note payable was recorded at $22.352 million. Stockholders' deficit was $10.341 million and accumulated deficit increased to $53.283 million. The company disclosed substantial doubt about its ability to continue as a going concern and noted it raised $3.726 million in its September 16, 2024 IPO. The company also completed a February 25, 2025 acquisition of DSS PureAir assets for $1.15 million paid in stock, adding inventory and Celios IP.
Impact BioMedical (NYSE:IBO) disclosed in an 8-K that it signed a Merger and Share Exchange Agreement on 21 June 2025 with Dr Ashleys Cayman, newly formed PubCo Dr Ashleys Limited and related entities.
Transaction structure: (i) Merger Sub will merge into Impact, making Impact a wholly-owned subsidiary of PubCo; (ii) immediately after, PubCo will acquire 100% of Dr Ashleys Cayman. Post-closing ownership will be 94.20 % Dr Ashleys Cayman shareholder, 4.80 % Impact shareholders and 1.00 % BMI Capital. A reverse stock split of Impact shares will occur immediately before closing to facilitate the exchange ratio.
Consideration mechanics: each Impact common share, preferred conversion share, option and warrant (after conversion/cancellation) will be exchanged for PubCo ordinary shares representing the 4.80 % aggregate stake. Impact must have ≥ $10,000 net cash and zero net debt at closing. NYSE American must conditionally approve listing of PubCo shares.
Governance changes: Impact will be renamed "Dr Ashleys USA Inc."; all current Impact directors and officers will resign. New board and officers for both Impact and PubCo will be designated by Dr Ashleys Cayman. Support agreements covering 86.81 % of Impact’s shares commit to vote in favour of the deal.
Key conditions & rights: customary accuracy of reps & warranties, absence of material adverse effect, effectiveness of a registration statement, no blocking injunctions, and termination rights for breach or superior proposals. A Transition Agreement with DSS, Inc. was executed to ensure orderly hand-over of operations.
The filing attaches the Merger Agreement (Exhibit 2.1), Voting Agreement (Exhibit 10.1) and Transition Agreement (Exhibit 10.2) for full terms.